[Modern magnetic resonance procedures for assessing tumor response].
Magnetic resonance imaging (MRI) is a mainstay in oncological imaging with respect to tumor detection, characterization and treatment monitoring. Besides quantifying metric changes of tumor tissue, a wide range of different other surrogate parameters of therapy response can be imaged and quantified by MRI. Early monitoring of treatment success is critical both for medical and economical reasons specifically with more expensive target-specific drugs entering the clinical arena. Dynamic contrast-enhanced (DCE) and steady state MRI can help to assess tumor perfusion and vessel permeability. The cellular state of tissue can be measured by diffusion-weighted imaging (DWI) and metabolic changes can be monitored by MR spectroscopy (MRS). New target-specific contrast agents potentially allow selective imaging of apoptotic events.This review aims to give a brief overview of new MR-based imaging approaches to assess tumor response to new target-specific therapy regimes, with special emphasis on anti-angiogenic and antivascular treatment effects.
Persigehl
T
T
Institut für Klinische Radiologie, Universitätsklinikum Münster, Albert-Schweitzer- Str. 33, 48149 Münster, Deutschland.
Heindel
W
W
Bremer
C
C
D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods* / Q000639:trends*; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D011379:Prognosis; D016896:Treatment Outcome